Molecular Breakthrough Links Parkinson’s and Prion Diseases

Summary: Researchers describe a complex molecular interaction between alpha-synuclein and the cellular prion protein PrPC.

Source: SISSA.

New research demonstrates a significant molecular connection between Parkinson’s-related synucleinopathies and prion diseases.

Parkinson’s disease and prion disorders differ dramatically in their causes and clinical progression, yet a team led by Professor Giuseppe Legname has uncovered an unexpected molecular link between the two. Their findings illuminate how two distinct proteins in neurons—aggregated α-synuclein and the cellular prion protein (PrPC)—interact in ways that influence both types of pathology.

α-Synuclein is the principal protein that aggregates in synucleinopathies, a group of neurodegenerative diseases that includes Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. The mechanisms by which α-synuclein aggregates form, enter cells, and spread through neural networks have long been unclear. The study published in Scientific Reports shows that α-synuclein amyloid fibrils exploit PrPC to gain entry into cells and to propagate from cell to cell.

Atomic force microscopy image of alpha-synuclein amyloid fibrils. Image credit: Denis Scaini.

Experimental evidence from both cell models and animal studies indicates that the presence of PrPC significantly enhances uptake of α-synuclein fibrils. Wild-type mice expressing PrPC show greater internalization and spreading of α-synuclein amyloids compared with PrP knockout animals. These results point to PrPC as an important mediator of α-synuclein cell entry and intercellular transmission, suggesting a direct molecular route by which synuclein pathology can propagate through the brain.

Interestingly, the interaction appears to be bidirectional in its pathological consequences. While PrPC facilitates α-synuclein spreading, the presence of α-synuclein fibrils interferes with replication of misfolded prion protein (PrPSc). In vitro and ex vivo experiments demonstrate that α-synuclein amyloids reduce prion deposition and block PrPSc replication in nerve cells. This inhibitory effect on prion propagation aligns with clinical observations: some patients diagnosed with prion disease who also present neuronal α-synuclein deposits tend to experience a slower progression of prion pathology.

About this neuroscience research article

The study was a collaborative effort that included researchers from SISSA, Fondazione Carlo Besta in Milan, ELETTRA Sincrotrone in Trieste, and the University of Trieste. The research team examined the molecular interplay between α-synuclein amyloids and PrPC to clarify mechanisms of uptake, spread, and reciprocal interference between the two misfolded protein species.

Source: Donato Ramani – SISSA
Image Source: Image credited to Denis Scaini.
Original Research: A study titled “α-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication” by Suzana Aulić and colleagues, published in Scientific Reports (published online August 30, 2017).

Cite this article

MLA: SISSA. “Molecular Link Between Parkinson’s and Prion Diseases Discovered.” Neuroscience News, 14 September 2017.

APA: SISSA (2017, September 14). Molecular Link Between Parkinson’s and Prion Diseases Discovered. Neuroscience News.

Chicago: SISSA. “Molecular Link Between Parkinson’s and Prion Diseases Discovered.” Neuroscience News. Accessed September 14, 2017.


Abstract

α-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication

The detailed molecular mechanism that governs how misfolded α-synuclein (α-Syn) accumulates and propagates in synucleinopathies remains incompletely understood. The present work demonstrates a role for the cellular prion protein (PrPC) in mediating the neuronal uptake and intercellular spread of recombinant α-synuclein amyloids. In vitro assays show that cells expressing PrPC internalize α-synuclein fibrils more efficiently than cells lacking PrPC; this observation is supported by in vivo comparisons between wild-type (Prnp+/+) and PrP knockout (Prnp−/−) mice. Notably, α-synuclein amyloids also inhibit replication of scrapie prions (PrPSc) in vitro and ex vivo, establishing a functional link between the two proteins. While PrPC promotes the internalization of α-synuclein fibrils, PrPSc replication is impaired when these fibrils are present. This interaction has potential clinical relevance because neuropathological reports indicate that Creutzfeldt–Jakob disease patients with concurrent α-synuclein deposits often show a more protracted disease course.

Authors: Suzana Aulić, Lara Masperone, Joanna Narkiewicz, Elisa Isopi, Edoardo Bistaffa, Elena Ambrosetti, Beatrice Pastore, Elena De Cecco, Denis Scaini, Paola Zago, Fabio Moda, Fabrizio Tagliavini & Giuseppe Legname. Published in Scientific Reports, August 30, 2017.

Feel free to share this neuroscience news.